Focusing on cancer

No drop today in shares of AstraZeneca and Bristol-Myers Squibb, with both hitting new 52-week highs for a time. That`s after AstraZeneca agree to buy out Bristol-Meyers stake in a partisanship to develop and sell a diabetes drug, allowing Bristol-Myers to focus on something else, like some new cancer drugs.

Morgan Brennan reports.

This entry was posted in Biotech & Pharmaceuticals, NBR Show Clips. Bookmark the permalink.

Leave a Reply